Population pharmacokinetics and pharmacogenetics of apatinib in adult cancer patients.

Xin-Mei YangPan-Pan YeXiao-Lin LiuZi-Xuan GuoMin KanQian LiLin-Lin SongHong-Ying LiuKe-Guang ChenJin-Yi ShiYe-Hui ZhangYa LiFu-Rong ZhaoJohn van den AnkerYan LiWei Zhao

Published in: British journal of clinical pharmacology (2023)

A population PK model of apatinib in adult cancer patients was established. CYP3A5 genotype and systemic cancer type had concurrent effects on PK parameters. CYP3A5 patients who do not express CYP3A5*1 required higher doses.

Keyphrases

childhood cancer
papillary thyroid
squamous cell carcinoma
young adults
lymph node metastasis